candesartan has been researched along with Bowel Diseases, Inflammatory in 1 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Garg, M | 1 |
| Royce, SG | 1 |
| Tikellis, C | 1 |
| Shallue, C | 1 |
| Batu, D | 1 |
| Velkoska, E | 1 |
| Burrell, LM | 1 |
| Patel, SK | 1 |
| Beswick, L | 1 |
| Jackson, A | 1 |
| Britto, K | 1 |
| Lukies, M | 1 |
| Sluka, P | 1 |
| Wardan, H | 1 |
| Hirokawa, Y | 1 |
| Tan, CW | 1 |
| Faux, M | 1 |
| Burgess, AW | 1 |
| Hosking, P | 1 |
| Monagle, S | 1 |
| Thomas, M | 1 |
| Gibson, PR | 1 |
| Lubel, J | 1 |
1 other study available for candesartan and Bowel Diseases, Inflammatory
| Article | Year |
|---|---|
Imbalance of the renin-angiotensin system may contribute to inflammation and fibrosis in IBD: a novel therapeutic target?
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Cell Proliferat | 2020 |